Clinical and genetic investigation in Chinese patients with demyelinating Charcot-Marie-Tooth disease
Jin He
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
Search for more papers by this authorLingling Guo
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorGuorong Xu
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorLiuqing Xu
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorShan Lin
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorWanjin Chen
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
Search for more papers by this authorCorresponding Author
Ning Wang
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
Correspondence
Ning Wang, MD, PhD, Department of Neurology, First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou 350005, China.
Email: [email protected]
Search for more papers by this authorJin He
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
Search for more papers by this authorLingling Guo
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorGuorong Xu
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorLiuqing Xu
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorShan Lin
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Search for more papers by this authorWanjin Chen
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
Search for more papers by this authorCorresponding Author
Ning Wang
Department of Neurology and Institute of Neurology, First Affiliated Hospital, Fujian Medical University, Fuzhou, China
Fujian Key Laboratory of Molecular Neurology, Fuzhou, China
Correspondence
Ning Wang, MD, PhD, Department of Neurology, First Affiliated Hospital, Fujian Medical University, 20 Chazhong Road, Fuzhou 350005, China.
Email: [email protected]
Search for more papers by this authorAbstract
Demyelinating Charcot-Marie-Tooth disease (CMT) is the most common subtype of CMT. It is caused mainly by 17p11.2 heterozygous duplication, but also by mutations in more than 20 genes which affect development and function of Schwann cells. To investigate the profile of genes mutated and clinical features in demyelinating CMT of Chinese descent, we collected a cohort of 44 demyelinating CMT patients and screened them using multiplex ligation-dependent probe amplification (MLPA) and targeted next-generation sequencing (NGS) technology. The MLPA technology revealed that 77.3% demyelinating CMT patients harbored 17p11.2 heterozygous duplication and 6.8% patients harbored heterozygous deletion of exon 6 of MPZ gene, that was further confirmed a novel c.674_675insA mutation in MPZ gene. In the patients with 17p12 heterozygous duplication, 3 sets of independent families were discordant for the CMT phenotype within the same family. The targeted NGS technology revealed that 6 candidate mutations including 1 previously reported mutation (GDAP1: c.571C>T) and 5 novel mutations (SBF2: c.415T>C, c.619G>T, c.1258A>G; GDAP1: c.589delC; PMP22: c.318delT) were found. In conclusion, combined MLPA technique with targeted NGS, the demyelinating CMT genetic diagnostic success rate was increased.
Supporting Information
| Filename | Description |
|---|---|
| jns12277-sup-0001-SuppInfo.xlsxExcel 2007 spreadsheet , 14 KB | Supplementary Material |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol. 2009; 8: 654-667.
- 2Tazir M, Hamadouche T, Nouioua S, Mathis S, Vallat JM. Hereditary motor and sensory neuropathies or Charcot-Marie-Tooth diseases: an update. J Neurol Sci. 2014; 347: 14-22.
- 3Mathis S, Goizet C, Tazir M, et al. Charcot-Marie-Tooth diseases: an update and some new proposals for the classification. J Med Genet. 2015; 52: 681-690.
- 4van Paassen BW, van der Kooi AJ, van Spaendonck-Zwarts KY, Verhamme C, Baas F, de Visser M. PMP22 related neuropathies: Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies. Orphanet J Rare Dis. 2014; 9: 38.
- 5Saporta AS, Sottile SL, Miller LJ, Feely SM, Siskind CE, Shy ME. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol. 2011; 69: 22-33.
- 6Rossor AM, Polke JM, Houlden H, Reilly MM. Clinical implications of genetic advances in Charcot-Marie-Tooth disease. Nat Rev Neurol. 2013; 9: 562-571.
- 7Rossor AM, Tomaselli PJ, Reilly MM. Recent advances in the genetic neuropathies. Curr Opin Neurol. 2016; 29: 537-548.
- 8Murphy SM, Herrmann DN, McDermott MP, et al. Reliability of the CMT neuropathy score (second version) in Charcot-Marie-Tooth disease. J Peripher Nerv Syst. 2011; 16: 191-198.
- 9Wang W, Guedj M, Bertrand V, et al. A Rasch analysis of the Charcot-Marie-Tooth neuropathy score (CMTNS) in a cohort of Charcot-Marie-Tooth type 1A patients. PLoS One. 2017; 12: e0169878.
- 10England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy: role of laboratory and genetic testing (an evidence-based review). Report of the American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, and American Academy of Physical Medicine and Rehabilitation. Neurology. 2009; 72: 185-192.
- 11Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA. 2015; 314: 2172-2181.
- 12Wang R, He J, Li JJ, et al. Clinical and genetic spectra in a series of Chinese patients with Charcot-Marie-Tooth disease. Clin Chim Acta. 2015; 451: 263-270.
- 13Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009; 25: 1754-1760.
- 14Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17: 405-424.
- 15Song S, Zhang Y, Chen B, et al. Mutation frequency for Charcot-Marie-tooth disease type 1 in the Chinese population is similar to that in the global ethnic patients. Genet Med. 2006; 8: 532-535.
- 16Sun B, Chen Z, Ling L, Yang F, Huang X. Clinical and genetic spectra of Charcot-Marie-Tooth disease in Chinese Han patients. J Peripher Nerv Syst. 2017; 22: 13-18.
- 17Abe A, Numakura C, Kijima K, Hayashi M, Hashimoto T, Hayasaka K. Molecular diagnosis and clinical onset of Charcot-Marie-Tooth disease in Japan. J Hum Genet. 2011; 56: 364-368.
- 18Hayashi M, Abe A, Murakami T, et al. Molecular analysis of the genes causing recessive demyelinating Charcot-Marie-Tooth disease in Japan. J Hum Genet. 2013; 58: 273-278.
- 19Choi BO, Lee MS, Shin SH, et al. Mutational analysis of PMP22, MPZ, GJB1, EGR2 and NEFL in Korean Charcot-Marie-Tooth neuropathy patients. Hum Mutat. 2004; 24: 185-186.
- 20Shahrizaila N, Samulong S, Tey S, et al. X-linked Charcot-Marie-Tooth disease predominates in a cohort of multiethnic Malaysian patients. Muscle Nerve. 2014; 49: 198-201.
- 21Boerkoel CF, Takashima H, Garcia CA, et al. Charcot-Marie-Tooth disease and related neuropathies: mutation distribution and genotype-phenotype correlation. Ann Neurol. 2002; 51: 190-201.
- 22Garcia CA, Malamut RE, England JD, Parry GS, Liu P, Lupski JR. Clinical variability in two pairs of identical twins with the Charcot-Marie-Tooth disease type 1A duplication. Neurology. 1995; 45: 2090-2093.
- 23Silander K, Meretoja P, Nelis E, et al. A de novo duplication in 17p11.2 and a novel mutation in the Po gene in two Dejerine-Sottas syndrome patients. Hum Mutat. 1996; 8: 304-310.
10.1002/(SICI)1098-1004(1996)8:4<304::AID-HUMU2>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 24Sanmaneechai O, Feely S, Scherer SS, et al. Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene. Brain. 2015; 138: 3180-3192.
- 25Ylikallio E, Johari M, Konovalova S, et al. Targeted next-generation sequencing reveals further genetic heterogeneity in axonal Charcot-Marie-Tooth neuropathy and a mutation in HSPB1. Eur J Hum Genet. 2014; 22: 522-527.
- 26Lupo V, Garcia-Garcia F, Sancho P, et al. Assessment of targeted next-generation sequencing as a tool for the diagnosis of Charcot-Marie-Tooth disease and hereditary motor neuropathy. J Mol Diagn. 2016; 18: 225-234.
- 27Nam SH, Hong YB, Hyun YS, et al. Identification of genetic causes of inherited peripheral neuropathies by targeted gene panel sequencing. Mol Cells. 2016; 39: 382-388.
- 28Azzedine H, Bolino A, Taieb T, et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet. 2003; 72: 1141-1153.
- 29Senderek J, Bergmann C, Weber S, et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth Neuropathy Type 4B2/11p15. Hum Mol Genet. 2003; 12: 349-356.
- 30Li J. Inherited neuropathies. Semin Neurol. 2012; 32: 204-214.
- 31Barankova L, Vyhnalkova E, Zuchner S, et al. GDAP1 mutations in Czech families with early-onset CMT. Neuromuscul Disord. 2007; 17: 482-489.
- 32Marco A, Cuesta A, Pedrola L, Palau F, Marin I. Evolutionary and structural analyses of GDAP1, involved in Charcot-Marie-Tooth disease, characterize a novel class of glutathione transferase-related genes. Mol Biol Evol. 2004; 21: 176-187.
- 33Russo M, Laura M, Polke JM, et al. Variable phenotypes are associated with PMP22 missense mutations. Neuromuscul Disord. 2011; 21: 106-114.
- 34Li J, Parker B, Martyn C, Natarajan C, Guo J. The PMP22 gene and its related diseases. Mol Neurobiol. 2013; 47: 673-698.
Citing Literature
